Psoriatic Arthritis

Top Story

Psoriasis, psoriatic arthritis patients showed similar rates of metabolic syndrome

June 23, 2017

MADRID — Patients with psoriatic arthritis and psoriasis had a similar prevalence of metabolic syndrome and hepatic stiffness, according to findings presented at the EULAR Annual Congress, here.

“What we know from the literature is that metabolic syndrome is more prevalent in psoriatic arthritis and psoriasis patients with respect to the general population,” presenter Augusta Ortolan, MD, said in a press conference. “The metabolic syndrome can also express itself at a hepatic level through non-alcoholic fatty liver disease, which normally can range from steatosis to hepatitis to fibrosis, in the later stage.”

EMA recommends approval of Humira biosimilar Imraldi

June 23, 2017
The European Medicines Agency has recommended the approval of the Imraldi, making it the third anti-TNF biosimilar candidate to receive a positive opinion from the…
Meeting News

Inhibition of radiographic progression independent of disease activity for adalimumab in PsA

June 22, 2017
MADRID — Inhibition of radiographic progression was independent of disease activity for adalimumab in patients with psoriatic arthritis, according to findings…
Meeting News

Severity of sonographic enthesitis seen as a marker of joint damage in PsA

June 21, 2017
MADRID — Severe enthesitis on sonography was associated with radiographic peripheral and axial joint damage in patients with psoriatic arthritis, according to a…
CME

Protocol-Based Arthroplasty: Less Is More: October 2015

Total joint arthroplasty is a successful orthopedic procedure that is performed in high volume in the United States and…
More »
Video
Meeting News Coverage

VIDEO: Researcher provides update on biosimilars

March 6, 2016
More »
Featured
EULAR Annual Congress

EULAR Annual Congress

CME CNE CPE CE

The Management of Comorbid Conditions in Patients with Rheumatoid Arthritis

Supported by an educational grant from Pfizer Inc.

Strong evidence demonstrates that patients with rheumatoid arthritis (RA) are at a high risk for developing several…
More »
Meeting News

Psoriasis, psoriatic arthritis patients showed similar rates of metabolic syndrome

June 23, 2017
MADRID — Patients with psoriatic arthritis and psoriasis had a similar prevalence of metabolic syndrome and hepatic stiffness, according to…

EMA recommends approval of Humira biosimilar Imraldi

June 23, 2017
The European Medicines Agency has recommended the approval of the Imraldi, making it the third anti-TNF biosimilar candidate to receive a positive…

Meeting News

Inhibition of radiographic progression independent of disease activity for adalimumab in PsA

June 22, 2017
MADRID — Inhibition of radiographic progression was independent of disease activity for adalimumab in patients with psoriatic arthritis…

Meeting News

Severity of sonographic enthesitis seen as a marker of joint damage in PsA

June 21, 2017
MADRID — Severe enthesitis on sonography was associated with radiographic peripheral and axial joint damage in patients with psoriatic…

Meeting News

In psoriatic arthritis, TNFi drug-level testing may predict 12-month response

June 21, 2017
MADRID — In psoriatic arthritis patients initiating an adalimumab regimen, tumor necrosis factor-alpha inhibitor drug-level testing may have…

Feature

Unspoken and Undiagnosed: Addressing Sex and Intimacy Issues in Rheumatic Disease

Healio Rheumatology, June 2017
Sexual dysfunction and intimacy issues may rank high among the complaints reported by patients with rheumatic diseases, but these complaints often…

Meeting News

Study: Pain persists even during treatment among patients with PsA

June 15, 2017
MADRID — Many patients with psoriatic arthritis being treated with biologic therapy reported ongoing pain, according to findings from a…

Meeting News

Tofacitinib reached musculoskeletal safety endpoints in PsA

June 15, 2017
MADRID — Two different dosing levels of tofacitinib bested placebo in response rate and safety parameters for patients with psoriatic…

Meeting News

Ixekizumab improved function, other parameters in treatment of PsA

June 15, 2017
MADRID — Improvements in arthritis outcomes, physical function and psoriasis were reported for treatment with ixekizumab among patients with…

Meeting News

Comorbidities may predict poor outcomes in patients with PsA

June 15, 2017
MADRID — The presence of baseline comorbidities was associated with adverse outcomes in psoriatic arthritis, including poor response to and…

More Headlines »
Advertisement
Advertisement